Investec to buy majority stake in Irish firm Neontar
Investec, the specialist banking group, is to take a majority stake in Neontar, the Irish corporate finance and wealth manager.
Investec, the specialist banking group, is to take a majority stake in Neontar, the Irish corporate finance and wealth manager.
Investec will pay around €32.35m for the controlling stake, which is being bought from a group of investors including Quinn Financial Services, and plans to extend the offer to all Neontar shareholders, with a view to securing 100% control.
Neontar owns the NCB Group, a corporate finance and wealth and investment company.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Investec says it will pay €4.35m over and above the net asset value of Neontar which is estimated at €28m. There may also be deferred payments to the sellers, dependant on the recovery of certain amounts by NCB. The deal looks likely to be done in cash although Investec says, at "its election", the payment could take the form of shares.
Completion of the deal is expected by the second quarter of 2012.
Investec shares have dropped 22.7% in the last 12 months.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge